.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Covington
Colorcon
Boehringer Ingelheim
Chubb
US Army
Argus Health
Medtronic
Federal Trade Commission
Express Scripts

Generated: September 26, 2017

DrugPatentWatch Database Preview

Bristol Myers Squibb Company Profile

« Back to Dashboard

What is the competitive landscape for BRISTOL MYERS SQUIBB, and when can generic versions of BRISTOL MYERS SQUIBB drugs launch?

BRISTOL MYERS SQUIBB has seventy-seven approved drugs.

There are eighteen US patents protecting BRISTOL MYERS SQUIBB drugs and there have been two Paragraph IV challenges on BRISTOL MYERS SQUIBB drugs in the past three years.

There are four hundred and fifty-three patent family members on BRISTOL MYERS SQUIBB drugs in fifty-eight countries.

Summary for Applicant: Bristol Myers Squibb

Patents:18
Tradenames:66
Ingredients:58
NDAs:77
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb
TERFONYL
trisulfapyrimidines (sulfadiazine;sulfamerazine;sulfamethazine)
SUSPENSION;ORAL006904-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
GLUCOPHAGE
metformin hydrochloride
TABLET;ORAL020357-004Nov 5, 1998DISCNYesNo► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
SPRYCEL
dasatinib
TABLET;ORAL021986-006Oct 28, 2010RXYesNo► Subscribe► Subscribe ► Subscribe
Bristol Myers Squibb
VIDEX
didanosine
TABLET, CHEWABLE;ORAL020154-003Oct 9, 1991DISCNYesNo► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
SUSTIVA
efavirenz
CAPSULE;ORAL020972-003Sep 17, 1998RXYesYes► Subscribe► SubscribeY► Subscribe
Bristol Myers Squibb
TESLAC
testolactone
TABLET;ORAL016118-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
SERZONE
nefazodone hydrochloride
TABLET;ORAL020152-002Dec 22, 1994DISCNYesNo► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
BARACLUDE
entecavir
TABLET;ORAL021797-001Mar 29, 2005ABRXYesNo► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
REYATAZ
atazanavir sulfate
POWDER;ORAL206352-001Jun 2, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
VIDEX
didanosine
TABLET, CHEWABLE;ORAL020154-004Oct 9, 1991DISCNYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Bristol Myers Squibb

Paragraph IV activity for BRISTOL MYERS SQUIBB drugs

Drugname Dosage Strength Tradename Submissiondate
apixaban
Tablets2.5 mg and 5 mg
ELIQUIS
12/28/2016
naloxone hydrochloride
Nasal Spray4 mg/spray
NARCAN
7/15/2016
dasatinib
Tablets80 mg and 140 mg
SPRYCEL
6/17/2011
dasatinib
Tablets80 mg and 140 mg
SPRYCEL
6/16/2011
dasatinib
Tablets20 mg, 50 mg, 70 mg and 100 mg
SPRYCEL
6/28/2010
entecavir
Tablets0.5 mg and 1 mg
BARACLUDE
6/14/2010
atazanavir sulfate
Capsules100 mg and 150 mg
REYATAZ
3/19/2010
atazanavir sulfate
Capsules200 mg
REYATAZ
2/16/2010
atazanavir sulfate
Capsules300 mg
REYATAZ
7/20/2009
efavirenz
Tablets600 mg
SUSTIVA
4/9/2009
pravastatin sodium
Tablets30 mg
PRAVACHOL
6/1/2005
didanosine
Delayed-release Capsules200 mg, 250 mg and 400 mg
VIDEX EC
6/1/2004

Non-Orange Book Patents for Bristol Myers Squibb

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,691,846Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
6,110,946 Antivirally active heterocyclic azahexane derivatives► Subscribe
8,470,854Lactam-containing compounds and derivatives thereof as factor XA inhibitors► Subscribe
7,091,223Cyclic protein tyrosine kinase inhibitors► Subscribe
7,189,854Cyclic protein tyrosine kinase inhibitors► Subscribe
6,979,694 Cyclic protein tyrosine kinase inhibitors► Subscribe
RE38629 Solid oral dosage form comprising a combination of metformin and glibenclamide► Subscribe
7,371,761Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
6,300,519 Antivirally active heterocyclic azahexane derivatives► Subscribe
7,960,411Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Bristol Myers Squibb Drugs

Country Document Number Estimated Expiration
Denmark1427415► Subscribe
Poland193822► Subscribe
Slovakia284655► Subscribe
HungaryS1300014► Subscribe
African Regional IP Organization (ARIPO)200001885► Subscribe
European Patent Office1056722► Subscribe
African Regional IP Organization (ARIPO)1450► Subscribe
Canada2519898► Subscribe
China1193010► Subscribe
Japan2002509136► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Bristol Myers Squibb Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0006France► SubscribePRODUCT NAME: PIOGLITAZONE/METFORMINE ET LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/06/354/001 DU 20060728; REGISTRATION NO/DATE AT EEC: EU/1/06/354/001 DU 20060728
11/024Ireland► SubscribePRODUCT NAME: AZTREONAM LYSINE; REGISTRATION NO/DATE: EU/1/09/543/001 20090923
888Luxembourg► Subscribe91888, EXPIRES: 20260518
00492Netherlands► SubscribePRODUCT NAME: AZTREONAM, NIET IN EEN SAMENSTELLING MET ARGININE, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN AZTREONAM, ANDERS DAN EEN ARGININEZOUT, IN HET BIJZONDER ALS AZTREONAMLYSINE; REGISTRATION NO/DATE: EU/1/09/543/001 20090921
C/GB08/033United Kingdom► SubscribePRODUCT NAME: TENOFOVIR DISOPROXIL AND THE SALTS (IN PARTICULAR THE FUMARATE), HYDRATES, TAUTOMERS AND SOLVATES THEREOF, TOGETHER WITH EMTRICITABINE AND EFAVIRENZ; REGISTERED: UK EU/1/07/430/001 20071213; REASON FOR LAPSE: SURRENDERED
146Luxembourg► SubscribePRODUCT NAME: DASATINIB ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES
90029-7Sweden► SubscribePRODUCT NAME: APIXABAN OCH FARMACEUTISKT ACCEPTABLA SALTER DAERAV; REG. NO/DATE: EU/1/11/691/001-005 20110518
C0021France► SubscribePRODUCT NAME: EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE; REGISTRATION NO/DATE: EU/1/07/430/001 20071213
2011012,C1427415Lithuania► SubscribePRODUCT NAME: APIXABANUM; REGISTRATION NO/DATE: EU/1/11/691/001 - EU/1/11/691/005, 0110518
1214076/01Switzerland► SubscribePRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
US Department of Justice
Express Scripts
Merck
Mallinckrodt
AstraZeneca
Argus Health
Medtronic
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot